It was a research purpose to estimate antihypertensive and nephroprotective effects of enalapril depending on the type of the mononucleotide polymorphism of М235Т gene AGT at hypertensive patients with saccharine diabetes of a 2 type.
Suboptimum antihypertensive and antiproteinuric the effects of enalapril in the category of the Т-monozygotic patients after the М235Т AGT polymorphism are predetermined by the necessity of the early setting of the combined antihypertensive therapy both with the purpose of nephroprotection and for the sake of decline of general risk of cardiovascular complications.